LLBO OTC
Lifeline Biotechnologies, Inc.
1W: +0.0%
1M: -20.0%
3M: -42.9%
YTD: -42.9%
1Y: -60.0%
3Y: +100.0%
5Y: -83.3%
$0.00
+0.00 (+33.33%)
Weekly Expected Move ±90.0%
$-0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$6K
-31.8% ▼
Net Income
-$6K
-114.8% ▼
EPS (Diluted)
$0.00
+0.0% ▲
EBITDA
-$6K
-114.8% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2017 | FY2018 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $350K | $0 | $0 | $0 | $0 |
| YoY Growth | +483.3% | -100.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $630 | $0 | $0 | $0 | $0 |
| Gross Profit | $349K | $0 | $0 | $0 | $0 |
| Gross Margin | 99.8% | — | — | — | — |
| R&D Expenses | $0 | $0 | $0 | $0 | $0 |
| SG&A Expenses | $107K | $43K | $6K | $4K | $6K |
| Operating Expenses | $107K | $43K | $6K | $4K | $6K |
| Operating Income | $242K | -$43K | -$6K | -$4K | -$6K |
| Operating Margin | 69.1% | — | — | — | — |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | $242K | -$43K | -$6K | -$3K | -$6K |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | $242K | -$43K | -$6K | -$3K | -$6K |
| Net Margin | 69.1% | — | — | — | — |
| EPS (Diluted) | $0.00 | $-0.00 | $0.00 | $0.00 | $0.00 |
| EBITDA | $243K | -$43K | -$6K | -$3K | -$6K |
| Shares Outstanding | 3.14B | 3.14B | 3.35B | 3.35B | 4.35B |